Nunes 1993.

Methods	Randomized, double‐blind, placebo‐controlled trial
Participants	26 depressed people with alcohol dependence (number of men and women: data not available; mean age: data not available) Inclusion criteria: current DSM‐III‐R diagnoses of depressive disorders (or dysthymia, or depressive disorder not otherwise specified) and alcohol dependence (or abuse) Exclusion criteria: information not available Participants with bipolar disorder: information not available
Interventions	Drugs: imipramine (dose: information not available; 13 participants) or placebo (10 participants) Psychotherapy: information not available Scheduled duration of treatment: 6 months Site: Depression Evaluation Service, New York State Psychiatric Institute, New York, NY, USA Setting: outpatients Route of administration: orally Starting dose: participants completed a previous open label study in which received a mean dose of 263 mg/day Pattern of dose reduction: information not available
Outcomes	Depression: data not available Alcohol dependence: data not available Global response Dropouts: data not available Adverse effects: data not available
Notes	Baseline characteristics of participants Depression: primary depression (rate of participants): 100% duration: information not available CGI score: 'much improved' or 'very much improved' after 1‐week of single‐blind placebo treatment Alcohol dependence: severity: information not available being actively drinking: participants were abstinent length of abstinence: approximately 12 weeks Other psychiatric comorbidity: information not available. Other substance use disorders: information not available. Other characteristics of study Other pharmacological treatment offered: information not available. Funding sources: supported in part by training grant MH‐15144 from NIMH, grants AA‐07688 and AA‐08030 from the National Institute on Alcohol Abuse and Alcoholism, and Scientist Development Award for Clinicians DA‐00154 from the National Institute on Drug Abuse. CIBA/Geigy provided imipramine and matching placebo. Declarations of interest: information not available Other information Only data of the double‐blind trial were included in the present meta‐analysis.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Information insufficient to permit judgement.
Allocation concealment (selection bias)	Unclear risk	Information insufficient to permit judgement.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement.
Blinding of outcome assessment (detection bias) objective	Low risk	No information on the blinding of outcome assessors.
Blinding of outcome assessment (detection bias) subjective	Unclear risk	No information on the blinding of outcome assessors.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement.
Selective reporting (reporting bias)	High risk	Not all of study's prespecified outcomes were reported.